Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Global Blood Therapeutics' Oxbryta Approved Broadly For Sickle Cell Disease

Executive Summary

Oxbryta is the second new drug for sickle cell disease approved in just over one week, but it was approved with a broad label for sickle cell disease while Novartis' Adakveo was approved for pain crises.

You may also be interested in...



As Bluebird’s CAR-T Competition Intensifies, Sickle Cell Therapy Brings Upside

While the BCMA-targeting CAR-T competition is grabbing attention, bluebird has good news in sickle cell therapy.

FDA Approval For Novartis’s Sickle Cell Treatment Adakveo

One of a new wave of treatments, Novartis has focused on proving its drug cuts vaso-occlusive crises (VOCs), or pain crises.

Sickle Cell Disease Market Snapshot: "The Time Has Come"

Three new drugs for sickle cell disease could be on the market in the US next year, representing a groundswell of advancement for the devastating blood disorder that has had limited options.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141243

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel